Patients may be enrolled prospectively, at the time of receiving Jelmyto, or after receiving Jelmyto for retrospective data capture and prospective follow up. Patients will be followed until 3 years after the first dose of Jelmyto or death.~Data will be captured to address specific clinical questions and data gaps related to real world use of Jelmyto.~Example clinical questions:~How is Jelmyto used in the real world setting?~What adverse events (AEs) and at what rates and time points are they observed in the real world setting?~What is the disease volume before and after resection/ablation prior to treating with Jelmyto?~Did the use of Jelmyto impact clinical decision making and management?~What is the complete response (CR) rate, duration of response, and rate of progression, including subgroups of interest?~What are the rates of, time to, and pathology at radical nephroureterectomy (RNU) by response to treatment and number of Jelmyto doses received?~What are outcomes for non-responders or partial responders? What are the rates of surgical and therapeutic treatment options received following response assessment, including additional Jelmyto?~What was the outcome of patients with solitary kidney and/or chronic kidney disease (CKD)? Did Jelmyto prevent dialysis by avoiding nephrectomy in solitary kidney or in patients with baseline CKD?~What is the rate and timing of bladder cancer occurrence and/or recurrences?
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.